Gyre Therapeutics (GYRE) Enterprise Value (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Enterprise Value for 17 consecutive years, with -$14.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 179.83% year-over-year to -$14.1 million; the TTM figure through Mar 2026 stood at -$14.1 million (down 179.83% YoY), while the FY2025 annual figure was -$4.0 million, down 147.77% from the prior year.
• Enterprise Value retreated to -$14.1 million in Q1 2026 per GYRE's latest filing, from -$4.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at $29.7 million in Q4 2022 and bottomed at -$75.4 million in Q2 2022.
• Historically, Enterprise Value has averaged -$6.2 million across 5 years, with a median of -$4.0 million in 2025.
• Annual changes were most pronounced in 2024 — Enterprise Value jumped 556.42% — and 2025, when it sank 341.0%.
• Gyre Therapeutics' Enterprise Value stood at $29.7 million in 2022, then slumped by 35.36% to $19.2 million in 2023, then slumped by 56.11% to $8.4 million in 2024, then tumbled by 147.77% to -$4.0 million in 2025, then slumped by 250.91% to -$14.1 million in 2026.
• Business Quant data shows GYRE's Enterprise Value at -$14.1 million in Q1 2026, -$4.0 million in Q4 2025, and -$24.5 million in Q3 2025.